Navigation Links
Protein shines light on cancer response
Date:2/24/2008

A technique that specifically tags tumors responding to chemotherapy may offer a new strategy for determining a cancer treatments effectiveness within days of starting treatment, according to a new study by Vanderbilt-Ingram Cancer Center investigators.

Appearing online ahead of print in Nature Medicine, the researchers report the identification of a small protein that specifically recognizes tumors responding to chemotherapy. They show that the protein, when tagged with a light-emitting molecule, can be used to visualize cancer response in mice just two days after starting therapy.

Improved monitoring of tumor response could help customize patient treatment and also speed up the development of new cancer drugs, said senior investigator Dennis Hallahan, M.D., the Ingram Professor of Cancer Research and chair of Radiation Oncology at Vanderbilt University Medical Center.

Currently, response to chemotherapy is determined by measuring changes in tumor size with imaging techniques like CT (computed tomography) and MRI (magnetic resonance imaging).

It takes two to three months of cancer therapy before we can determine whether the therapy has been effective for a patient, he said. If we can get that answer within one to two days, we can switch that patient to an alternative regimen very quickly.

Rapid assessment of tumor response is especially important now, Hallahan says, given recent advances in molecular targeted therapies chemotherapy medications that specifically interfere with the growth and proliferation of cancer cells while avoiding damage to healthy cells.

We now have so many molecular targeted drugs to choose from, and that number is growing every year, so we are now at a point where a patient can be switched from one regimen to another, he said. But we need the tools to make the decision to use an alternative therapy with the patient.

To find a rapid and noninvasive method to assess cancer response to these therapies, Hallahan focused not on tumor size, but molecular and cellular changes in responding tumors.

From a panel of billions of protein fragments, or peptides, Hallahan and colleagues identified one that specifically bound to tumors responding to therapy. To this peptide, they attached a light-emitting molecule and injected these labeled peptides into mice that had been implanted with human tumors.

Using specialized imaging cameras that detect light in the near-infrared range (invisible to the human eye), the investigators saw that tumors responding to therapy were brighter than non-responding tumors. The peptide detected response in a wide range of tumors brain, lung, colon, prostate and breast within two days of initiation of treatment.

The key word here is days, Hallahan said. This will allow us to minimize the duration of treatments with ineffective regimens in cancer patients.

The next step will be to move the technology into humans. The imaging technique used in mice (near-infrared) is not sensitive enough to penetrate deeply into human tissues, so the researchers are adapting the technology to an imaging modality commonly used in humans, called PET (positron emission tomography).

This imaging peptide will enter clinical trials within about 18 months, Hallahan said. The purpose, when we bring it into people, is to ask a very simple question: can we image responding cancers in people as well as we can in mice?

If so, he says that he suspects that such molecular imaging methods could help accelerate the development of new chemotherapeutic drugs.

In the pharmaceutical industry, well have a patient on a drug for months before we can re-evaluate the size of the tumor, Hallahan said. If we can get that answer within a couple of days, it will speed cancer drug development in the early phases of clinical trials.


'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. 3 newly discovered ERK pathway proteins related to CagA induced disease
2. U of M researchers determine structure of protein that mutates DNA of the AIDS virus HIV-1
3. Oncoproteins double-team and destroy vital tumor-suppressor
4. Lack of Brain Protein May Explain Rain Man Abilities
5. Discovery of overdrive protein could broaden drug design options
6. Burn Fat with fucoPROTEIN(TM) Bars
7. Unsuspected protein determines resistance to breast cancer treatment
8. Breaking down Huntingtons disease one protein at a time
9. New findings show Enbrel significantly reduced levels of C-reactive protein
10. Protein Linked With Poor Prognosis in Early-Stage Breast Cancer
11. Deafness and seizures result when mysterious protein deleted in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology: